Rein Therapeutics Inc. (RNTX) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Medical - Pharmaceuticals industria. La empresa tiene su sede en Austin, TX, United States. El CEO actual es James Brian Windsor.
RNTX tiene fecha de IPO 2017-06-29, 11 empleados a tiempo completo, cotiza en el NASDAQ Global Market, una capitalización de mercado de $45.7M.
Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.
